Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

w.alexza.com/about/the-staccato-system/staccato-animation">here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted a New Drug Application (NDA) in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and anticipates meeting with the FDA in the fourth quarter of 2010 to discuss the CRL.

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document.  The Company's guidance in this release is as of November 9, 2010 and financial guidance relating to the Company's current cash, cash equivalents and investments is as of September 30, 2010.

This news release contains forward-looking statements that involve significant risks and uncertainties, including our ability to establish a path for AZ-004 approval after meeting with the FDA. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be co
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
(Date:9/30/2014)... Netherlands , Sept. 30, 2014  eHealth, ... phone storage and access of this information, has ... Slot , however, that has not translated into ... http://photos.prnewswire.com/prnh/20140929/149122 Photo - http://photos.prnewswire.com/prnh/20140929/149123 ... the past few years developing MWD® Health Manager ...
(Date:9/30/2014)... 30, 2014 It is evident from the industry ... not performing upto expectations due to the lack of promotional ... the intake of omega-3 fatty acids. Among omega-3 ingredient sources ... oil, attributed to the large vegetarian population in ... fatty acid (PUFAs) ingredients is in growth stage of its ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... FRANCISCO, Oct. 29 Medivation, Inc. (Nasdaq: MDVN ... webcast with management to discuss third quarter 2010 financial results ... at 4:30 p.m. Eastern Time. A press release for the ... markets close on November 5, 2010. Interested ...
... N.Y., Oct. 29 Henry Schein, Inc. (Nasdaq: ... to office-based practitioners, today reported record financial results for the ... the third quarter of 2010 were $1.9 billion, an increase ... consists of 16.4% growth in local currencies and a decline ...
Cached Medicine Technology:Henry Schein Reports Record Third Quarter Results 2Henry Schein Reports Record Third Quarter Results 3Henry Schein Reports Record Third Quarter Results 4Henry Schein Reports Record Third Quarter Results 5Henry Schein Reports Record Third Quarter Results 6Henry Schein Reports Record Third Quarter Results 7Henry Schein Reports Record Third Quarter Results 8Henry Schein Reports Record Third Quarter Results 9Henry Schein Reports Record Third Quarter Results 10Henry Schein Reports Record Third Quarter Results 11
(Date:9/30/2014)... Austin, TX (PRWEB) September 30, 2014 ... for Facial Plastic Surgery, has been approved to be ... of Facial Plastic and Reconstructive Surgery (AAFPRS) fellowship program. ... their meeting in Orlando, Florida. , The Educational and ... throughout the medical community. It represents the finest postgraduate ...
(Date:9/30/2014)... 30, 2014 Neuromuscular and central ... the United States and worldwide. It is estimated ... diagnosed each year, adding to the more than ... Approximately 400,000 people in the US are affected ... to these statistics the 2.4 percent of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... caring individuals, National Children’s Oral Health Foundation: ... in grants to non-profit clinical partners. These ... Network and deliver comprehensive educational, preventive and ... Recipients include:,     Just Kids ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Pivotal 5, ... solutions, today announced Life Time – The Healthy Way ... destination for KettleWorX Group Training . KettleWorX Group ... fitness facilities. KettleWorX offers consumers of all fitness levels ... fun and effective manner. The rollout to Life Time ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Herceptin is the best drug ... and should remain the standard of care for that ... long-term clinical trial. HER2-positive breast cancers tend to ... according to the Mayo Clinic. For the study, ... Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to standard ...
Breaking Medicine News(10 mins):Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3
... blood pressure is well known, however// a new study reports ... published today in the Open Access journal Environmental Health for ... of salt particles can have just the same effect on ... an occupational health hazard for workers in salt factory. It ...
... Authority (NPPA) has been working// on bringing down the ... the manufacturers and has finally succeeded. According to NPPA ... bring about a price reduction ranging between 2.14% to ... hearing to explain the reasons for steep price increase ...
... Gengraine Technologies (Avesthagen) of India is collaborating// with ... Developing Countries (IFU) of Germany for Osteoporosis research. ... euro. Avesthagen said “"The alliance will cover diagnosis, ... disorders.” The research studies related to menopause linked ...
... patients with diastolic heart failure increases// the survival rate ... ,William C. Little and his research team from ... heart failure (DHF) treated with statins has better survival ... failure patients published in the Journal Circulation: Journal of ...
... For the elderly population, adjusting to the raising temperatures// in ... heat that may affect the elderly people are heat exhaustion ... Health Letter from the Harvard Medical School had given some ... a little easier during the summers. ,In addition to ...
... article reviewing the research carried out so far into the ... revealed that a new phase III trial is scheduled to ... CoQ10 has escalated, causing soaring prices and reports of fake ... to have been triggered by the publication of Shults’ earlier ...
Cached Medicine News:Health News:Hypertension can be caused by Inhalation of Salt 2Health News:Hypertension can be caused by Inhalation of Salt 3Health News:Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients 2Health News:Elderly People Needs To Tackle The Heat Effectively 2Health News:New Study to look at the Beneficial Effects of Coenzyme Q10 on Parkinson’s disease 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: